Neurology
Multiple Sclerosis — Acute Relapse
Define relapse, exclude pseudo-relapse, IV/oral methylprednisolone, plasma exchange in refractory, disease-modifying therapy review.
Source: ABN 2024; NICE NG220
Step 1 of ~4
info
Define Relapse
New/worsening neurological symptom lasting ≥24h, ≥30 days from previous relapse, in the absence of fever/infection/exhaustion (which can unmask old deficit — pseudo-relapse). Exclude UTI, viral illness, hyperthermia (Uhthoff's phenomenon).
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Dimethyl Fumarate · Disease-Modifying Therapy — Relapsing-Remitting Multiple Sclerosis
- Ocrelizumab · Multiple Sclerosis — Disease-Modifying Therapy
- Fingolimod · Multiple Sclerosis — Disease-Modifying Therapy
- Alemtuzumab · Multiple Sclerosis — Disease-Modifying Therapy
- Cladribine · Multiple Sclerosis — Disease-Modifying Therapy
- Ofatumumab · Multiple Sclerosis — Disease-Modifying Therapy
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Suspected Subarachnoid Haemorrhage · NICE NG228; RCEM 2023; AHA/ASA 2023
- Adult Head Injury · NICE NG232 (2023)
- Bell's Palsy / Facial Nerve Palsy · ENT UK 2017; AAN
- Vertigo Workup · ENT UK; NICE CKS
Decision support only. Always apply local guidelines and clinical judgement.